Pulmonary hypertension marker and application thereof as therapeutic target

Abstract

The invention relates to a pulmonary hypertension marker and application thereof as a therapeutic target, in particular to the application of a NOC4L gene as the pulmonary hypertension marker and thetherapeutic target. The marker reveals the correlation between the NOC4L gene and pulmonary hypertension for the first time, uses NOC4L overexpression, NOC4L knockout mice and wild type mice to carryout continuous hypoxic environmental treatment, establishes a mouse pulmonary hypertension model, and finds that NOC4L gene overexpression significantly reduces a right ventricular systolic pressure,and significantly increases a right ventricular hypertrophy index and a pulmonary vascular remodeling rate, a right ventricular systolic pressure, a right ventricular hypertrophy index and a pulmonaryvascular remodeling rate of the NOC4L knockout mice. The marker provides a novel target for the research and development of novel drugs for the treatment of the pulmonary hypertension.

Description

technical field [0001] The present invention relates to the field of biomedical engineering, specifically, a pulmonary hypertension marker and its application as a therapeutic target, especially the application of NOC4L gene as a pulmonary arterial hypertension marker and its therapeutic target. Background technique [0002] Pulmonary hypertension (PH) is a disease or pathophysiological syndrome in which the pressure in the pulmonary artery is abnormally increased due to known or unknown reasons. There are pulmonary circulation disorders and high right heart load, which can lead to right heart failure and even death. Pulmonary hypertension is common in clinical practice and is a health care problem that seriously endangers people's health. Arterial hypertension is a very serious disease. 75% of the patients were concentrated in the 20-40 age group, and 15% of the patients were under the age of 20. Symptoms of pulmonary hypertension include: shortness of breath, fatigue eas...

AI Technical Summary

Problems solved by technology

Some anticoagulant drugs, diuretics, digitalis, and supportive treatments such as oxygen inhalation are not effective

Some targeted drugs have been gradually developed in recent years, such as bosentan, ambrisentan, iloprost, etc. Most of them are aimed at patients with type 1 and 4 pulmonary arterial hypertension, with many adverse reactions and high risks

However, interventional therapy and surgical therapy are only for a small number of patients with pulmonary arterial hypertension, and the risk is high, and there are many sequelae after surgery.

Images